The estimated Net Worth of Terry Dagnon is at least $5.68 millió dollars as of 20 April 2023. Mr Dagnon owns over 520,000 units of Outlook Therapeutics Inc stock worth over $4,590,998 and over the last 5 years he sold OTLK stock worth over $788,466. In addition, he makes $300,000 as Chief Operations Officer at Outlook Therapeutics Inc.
Mr has made over 6 trades of the Outlook Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 520,000 units of OTLK stock worth $592,800 on 20 April 2023.
The largest trade he's ever made was selling 520,000 units of Outlook Therapeutics Inc stock on 20 April 2023 worth over $592,800. On average, Mr trades about 64,480 units every 80 days since 2020. As of 20 April 2023 he still owns at least 653,058 units of Outlook Therapeutics Inc stock.
You can see the complete history of Mr Dagnon stock trades at the bottom of the page.
Terry Dagnon is the Chief Operations Officer at Outlook Therapeutics Inc.
As the Chief Operations Officer of Outlook Therapeutics Inc, the total compensation of Mr Dagnon at Outlook Therapeutics Inc is $300,000. There are 4 executives at Outlook Therapeutics Inc getting paid more, with Lawrence Kenyon having the highest compensation of $1,863,900.
Mr Dagnon is 59, he's been the Chief Operations Officer of Outlook Therapeutics Inc since . There are 5 older and 7 younger executives at Outlook Therapeutics Inc. The oldest executive at Outlook Therapeutics Inc is Ralph H. Thurman, 72, who is the Independent Exec. Chairman.
Terry's mailing address filed with the SEC is C/O OUTLOOK THERAPEUTICS, INC., 485 ROUTE 1 SOUTH, BUILDING F, SUITE 320, ISELIN, NJ, 08830.
Over the last 6 years, insiders at Outlook Therapeutics Inc have traded over $1,453,842 worth of Outlook Therapeutics Inc stock and bought 29,698,365 units worth $33,411,235 . The most active insiders traders include Pte Ltd.Pillai Arun Kumar S..., Ghiath M.Gms Ventures & Inv... és Ventures Llc Syntone. On average, Outlook Therapeutics Inc executives and independent directors trade stock every 43 days with the average trade being worth of $11,985,869. The most recent stock trade was executed by Ventures Llc Syntone on 15 April 2024, trading 714,286 units of OTLK stock currently worth $5,021,431.
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
Outlook Therapeutics Inc executives and other stock owners filed with the SEC include: